Novel antisense oligonucleotides targeting TGF-β inhibit in vivo scarring and improve surgical outcome

Gene Therapy

Volumn 10, Issue 1, 2003, Pages 59-71

  Cordeiro, M F ^a   Mead, A ^e   Ali, R R ^b   Alexander, R A ^a   Murray, S ^e   Chen, C ^c   York Defalco, C ^e   Dean, N M ^c   Schultz, G S ^d   Khaw, P T ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c ISIS PHARMACEUTICALS   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e NONE

Author keywords

Antisense therapy; Scarring; TGF

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; FLUOROURACIL; MITOMYCIN C; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONJUNCTIVA DISEASE; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; EYE SURGERY; GENE THERAPY; GLAUCOMA; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RABBIT; REVIEW; SCAR FORMATION; TREATMENT OUTCOME; WOUND HEALING;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CICATRIX; CORNEA; FEMALE; FILTERING SURGERY; GENE THERAPY; GLAUCOMA; INJECTIONS; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN ISOFORMS; RABBITS; RANDOM ALLOCATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SEQUENCE ANALYSIS, DNA; TRANSFORMING GROWTH FACTOR BETA; WOUND HEALING;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0037266027     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301865     Document Type: Review

References (63)

1. Thylefors B, Negrel A. The global impact of glaucoma. Bulletin World Health Org 1994; 72: 323-326.
2. Foster A, Johnson GJ. Magnitude and causes of blindness in the developing world. Int Ophthalmol 1990; 14: 135-140.
3. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389-393.
4. Sommer A. Glaucoma: facts and figures (Doyne lecture). Eye 1996; 10: 295-301.
5. Jay JL. Rational choice of therapy in primary open angle glaucoma. Eye 1992; 6: 243-247.
6. Migdal C, Gregory W, Hitchings RA. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994; 101: 1651-1656.
7. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 490-491.
8. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol 1983; 101: 795-798.
9. Hitchings RA, Grierson I. Clinico pathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc UK 1983; 103: 84-88.
10. Stamper RL, McMenemy MG, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol 1992; 114: 544-553.
11. Parrish R, Minckler D. Late endophthalmitis - filtering surgery time bomb? Ophthalmology 1996; 103: 1167-1168.
12. Jampel HD, Pasquale LR, Dibernardo C. Hypotony maculopathy following trabeculectomy with mitomycin C. Arch Ophthalmol 1992; 110: 1049-1150.
13. Ashcroft GS et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med 1997; 3: 1209-1215.
14. Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995; 108: 985-1002.
15. Levine JH, Moses HL, Gold LI, Nanney LB. Spatial and temporal patterns of immunoreactive transforming growth factor-beta-1, -beta-2 and -beta-3 during excisional wound repair. Am J Pathol 1993; 143: 368-380.
16. Merwin JR et al. Vascular cell responses to TGF-β3 mimic those of TGF-β1 in vitro. Growth Factors 1991; 5: 149-158.
17. Lutty GA et al. Heterogeneity in localization of isoforms of TGF-beta in human retina, vitreous and choroid. Invest Ophthalmol Vis Sci 1993; 34: 477-487.
18. Pasquale LR et al. Immunolocalisation of TGF-beta1, TGF-beta2 and TGF-beta3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci 1993; 34: 23-30.
19. Imanishi J et al. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res 2000; 19: 113-129.
20. Connor TB et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest 1989; 83: 1661-1666.
21. Kon CH, Occleston NL, Aylward GW, Khaw PT. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 1999; 40: 705-712.
22. Carrington L, McLeod D, Boulton M. IL-10 and antibodies to TGF-beta2 and PDGF inhibit RPE-mediated retinal contraction. Invest Ophthalmol Vis Sci 2000; 41: 1210-1216.
23. Lee EH et al. Overexpression of the transforming growth factor-beta-inducible gene betaig-h3 in anterior polar cataracts. Invest Ophthalmol Vis Sci 2000; 41: 1840-1805.
24. Nishi O, Nishi K, Wada K, Ohmoto Y. Expression of transforming growth factor (TGF)-alpha, TGF-beta(2) and interleukin 8 messenger RNA in postsurgical and cultured lens epithelial cells obtained from patients with senile cataracts. Graefes Arch Clin Exp Ophthalmol 1999; 237: 806-811.
25. Saika S et al. Immunolocalization of TGF-beta1, -beta2, and -beta3, and TGF-beta receptors in human lens capsules with lens implants. Graefes Arch Clin Exp Ophthalmol 2000; 238: 283-293.
26. Cordeiro MF, Gay JA, Khaw PT. Human anti-TGF-β2 monoclonal antibody: a new anti-scarring agent for glaucoma filtration surgery. Invest Ophthalmol Vis Sci 1999; 40: 2225-2234.
27. Cordeiro MF et al. TGF-β1, -β2 & -β3 in vivo: effects on normal and Mitomycin-C modulated conjunctival scarring. Invest Ophthalmol Vis Sci 1999; 40: 1975-1982.
28. Cordeiro MF, Bhattacharya SS, Schultz GS, Khaw PT. TGF-β1, -β2 & -β3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation & migration. Invest Ophthalmol Vis Sci 2000; 41: 756-763.
29. Siriwardena D et al. Human anti-transforming growth factor beta-2 monoclonal antibody - a new modulator of wound healing in trabeculectomy: a randomised placebo controlled clinical study. Ophthalmology 2002; 109: 427-431.
30. Tamm I, Dorken B, Hartmann G. Antisense therapy in oncology: new hope for an old idea? Lancet 2001; 358: 489-497.
31. Orr RM. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision. Curr Opin Mol Ther 2001; 3: 288-294.
32. Lang KA, Peppercorn MA. Promising new agents for the treatment of inflammatory bowel disorders. Drugs R D 1999; 1: 237-244.
33. Yacyshyn BR et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998; 114: 1133-1142.
34. Crooke ST. Basic principles of antisense technology In: Crooke ST (ed). Antisense Drug Technology: Principles, Strategies and Applications. Marcel Dekker: New York, 2001, pp 1-28.
35. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978; 75: 285-288.
36. Dean NM, Butler M, Monia BF, Manoharan M. Pharmacology of 2′-O-(2-methoxy) ethyl-modified antisense oligonucleotides. In: Crooke ST (ed). Antisense Drug Technology: Principles, Strategies and Applications. Marcel Dekker: New York, 2001, pp 319-338.
37. Dean NM, Griffey RH. Identification and charecterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Develop 1997; 7: 229-233.
38. Reichel MB et al. New model of conjunctival scarring in the mouse eye. Br J Ophthalmol 1998; 82: 1072-1077.
39. Cordeiro MF et al. Role of TGF-β in conjunctival scarring. Clin Sci 2002 (in press).
40. Cordeiro MF et al. The effect of varying mitomycin-c treatment area in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 1997; 38: 1639-1646.
41. Reichel ML et al. A new model of conjunctival scarring in the mouse eye. Invest Ophthalm Vis Sci 1996; 37: 91.
42. Flanders KC, Holder MG, Winokur TS. Autoinduction of mRNA and protein expression for transforming growth factor-beta S in cultured cardiac cells. J Mol Cell Cardiol 1995; 27: 805-812.
43. Cordeiro MF. Beyond Mitomycin - TGF-β and wound healing. Prog Ret Eye Res 2002; 21: 75-89.
44. Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factor-beta in human aqueous humor. Curr Eye Res 1990; 9: 963-969.
45. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res 1994; 59: 723-727.
46. Picht G, Welge-Luessen U, Grehn F, Lutjen-Drecoll E. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol 2001; 239: 199-207.
47. Knisely TL, Bleicher PA, Vibbard CA, Granstein RD. Production of latent transforming growth factor-beta and other inhibitory factors by cultured murine iris and ciliary body cells. Curr Eye Res 1991; 10: 761-771.
48. Tripathi RC, Chan WF, Li J, Tripathi BJ. Trabecular cells express the TGF-beta 2 gene and secrete the cytokine. Exp Eye Res 1994; 58: 523-538.
49. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000; 14: 627-644.
50. Lee SB et al. Suppression of TGF-beta signaling in both normal conjunctival fibroblasts and pterygial body fibroblasts by amniotic membrane. Curr Eye Res 2000; 20: 325-334.
51. Obata H, Kaburaki T, Kato M, Yamashita H. Expression of TGF-beta type I and type II receptors in rat eyes. Curr Eye Res 1996; 15: 335-340.
52. Wrana JL et al. Mechanism of activation of the TGF-beta receptor. Nature 1994; 370: 341-347.
53. Nakao A et al. TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 1997; 16: 5353-5362.
54. Piek E, Heldin CH, Ten Dijke P. Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J 1999; 13: 2105-2124.
55. Rotzer D et al. Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor. EMBO J 2001; 20: 480-490.
56. The Fluorouracil Filtering Surgery Study Group. Fluorouracil Filtering Surgery Study one-year follow-up. Am J Ophthalmol 1989; 108: 625-635.
57. Kitazawa Y, Kawase K, Matsushita H, Minobe M. Trabeculectomy with mitomycin: a comparative study with fluorouracil. Arch Ophthalmol 1991; 109: 1693-1698.
58. Katz GJ et al. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. Ophthalmology 1995; 102: 1263-1269.
59. Lamping KA, Belkin JK. F5-Fluorouracil and mitomycin C in pseudophakic patients. Ophthalmology 1995; 102: 70-75.
60. Belyea DA et al. Late onset of sequential multifocal bleb leaks after glaucoma filtration surgery with 5-fluorauracil and mitomycin-C. Am J Ophthalmol 1997; 124: 40-45.
61. Greenfield DS, Liebmann JM, Jee J, Ritch R. Late-onset bleb leaks after glaucoma filtering surgery. Arch Ophthalmol 1998; 116: 443-447.
62. Kupin TH et al. Adjunctive mitomycin C in primary trabeculectomy in phakic eyes. Am J Ophthalmol 1995; 119: 30-39.
63. Crowston JG et al. Antimetabolites-induced apoptosis in Tenon's capsule fibroblasts. Invest Ophthalmol Vis Sci 1998; 39: 449-454.